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Broadly neutralizing HIV antibodies are much sought
after (a) to guide vaccine design, both as templates
and as indicators of the authenticity of vaccine candi-
dates, (b) to assist in structural studies, and (c) to
serve as potential therapeutics. However, the num-
ber of targets on the viral envelope spike for such
antibodies has been limited. Here, we describe a
set of human monoclonal antibodies that define
what is, to the best of our knowledge, a previously
undefined target on HIV Env. The antibodies recog-
nize a glycan-dependent epitope on the prefusion
conformation of gp41 and unambiguously distin-
guish cleaved from uncleaved Env trimers, an
important property given increasing evidence that
cleavage is required for vaccine candidates that
seek to mimic the functional HIV envelope spike.
The availability of this set of antibodies expands the
number of vaccine targets on HIV and provides re-
agents to characterize the native envelope spike.
INTRODUCTION
Broadly neutralizing antibodies (bnAbs) to highly antigenically
variable viruses such as HIV, influenza virus, and HCV haveattracted much attention in recent years because they provide
newopportunities to counter a particularly troublesome category
of pathogens (Burton et al., 2012; Kwong and Mascola, 2012;
Klein et al., 2013). Researchers are using such antibodies to
guide vaccine design for these pathogens by defining conserved
epitopes that can then be presented to the immune systemunder
more favorable conditions than typically occur in natural infection
or in most conventional vaccination approaches. For example,
grafting conserved epitopes into molecular scaffolds as candi-
date immunogens is one approach under intense study (Jardine
et al., 2013; Kulp andSchief, 2013). BnAbs have also been critical
in native envelope-protein structural studies, notably for HIV
(Julien et al., 2013a; Lyumkis et al., 2013), HCV (Kong et al.,
2013a), Ebola virus (Lee et al., 2008), and RSV (McLellan et al.,
2013). Finally, there is increasing evidence of the potential of
bnAbs as therapeutics (Buchacher et al., 1992; Klein et al.,
2012b; Barouch et al., 2013; Shingai et al., 2013). However, the
number of targets identified by bnAbs is limited, and the discov-
ery of more targets would be of considerable value for vaccine
design, structural studies, and therapeutic applications.
For HIV, bnAbs that recognize a gp41 region close to the virus
membrane (the membrane proximal external region, or MPER)
(Muster et al., 1993; Zwick et al., 2001; Huang et al., 2012), the
CD4 binding site (CD4bs) of gp120 (Barbas et al., 1992; Burton
et al., 1994; Zhou et al., 2010; Scheid et al., 2011; Wu et al.,
2011), a gp120 V2 loop region including the glycan at N160
(Walker et al., 2009, 2011), and a gp120 region centered on the
glycan atN332 (Buchacher et al., 1994; Trkola et al., 1996;WalkerImmunity 40, 657–668, May 15, 2014 ª2014 Elsevier Inc. 657
Figure 1. PGT151-158 Neutralization of an Indicator Panel of Five Pseudoviruses
Serial dilutions of antibody were preincubated with pseudovirus for 1 hr and then added to TZM-bl cells. Three days after infection luciferase values were
measured, and percent neutralization was calculated. Data are from one representative experiment of at least two replicate experiments and are presented as the
mean of two replicate wells ± SEM.
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PGT151 Binds a gp41 Epitope on Cleaved HIV Trimeret al., 2011) have been identified. Two other potential bnAb sites,
the first possibly involving the V3 loop and the coreceptor site of
gp120 (Klein et al., 2012a) and the second possibly involving the
CD4bs of gp120 and the N-trimer structure on gp41 (Zhang et al.,
2012), have been described but only partially characterized. We
have previously isolated a number of potent broadly neutralizing
monoclonal antibodies to the V2 and N332 regions from HIV-
infected donors (Walker et al., 2009, 2011). These antibodies
were isolated by direct functional screening rather than by anti-
gen selection (Scheid et al., 2009). In this method, IgG+ memory
Bcells from thedonorwereplated at approximately a singleBcell
per well, and after activation for 7–8 days, supernates were
screened for their ability to neutralize indicator viruses. Anti-
body-variable-region genes were rescued from positive wells
by PCR, and IgG molecules were expressed for further studies.
Here,weapplied this approach toanHIV-infecteddonorwhose
outstanding potency and breadth of serum led to classification of
the donor as an ‘‘elite neutralizer’’ (Simek et al., 2009; Walker
et al., 2010). We describe a set of antibodies that specifically
recognize cleavedHIVEnv trimer via a glycan-dependent epitope
expressed on the prefusion form of gp41. The antibodies bind a
previously undefined region on Env and thus provide a target
that could be useful in the development of immunogens for HIV
vaccine design. Furthermore, the antibodies can help to distin-
guish between native and nonnative conformations of Env immu-
nogens, facilitating the selection of appropriate immunogens.
RESULTS
Isolation of Antibodies PGT151–158, which Show Broad
Neutralization of HIV
By direct functional screening of supernatants derived from acti-
vated memory B cells from an elite neutralizer infected with a658 Immunity 40, 657–668, May 15, 2014 ª2014 Elsevier Inc.clade C virus, we identified antibodies that showed notable
neutralizing activity against a small set of viruses, JR-CSF
(clade B), 93IN905 (clade C), and IAVI C22 (clade C), which we
chose because they were potently neutralized by the donor’s
serum. Eight related antibody sequences, designated PGT151–
158 (the PGT151 family; Table S1), were retrieved from positive
wells, expressed, and found to have cross-clade neutralization
activity against a small panel of five indicator viruses in a TZM-
bl pseudovirus-neutralization assay (Simek et al., 2009; Walker
et al., 2010). The heavy-chain-complementarity-determining re-
gion 3 s (HCDR3s) of thePGT151 familywas found tobe 28amino
acids in length, an unusual feature sharedby severalHIV-1bnAbs
targeting glycan-dependent epitopes and the MPER on gp41
(Mascola and Haynes, 2013). As shown in Figure 1, most of the
antibodies neutralized four of the five viruses in the indicator
panel, but none neutralized the clade B isolate 92BR020. A
notable feature of the neutralization curves for some of the
antibody-isolate combinations was that, although IC50 values
indicated potent activity, 100% neutralization was not achieved.
In a number of cases, neutralization saturation occurred in the
range of 50%–80%, although there were some cases with lower
saturation, particularly against the clade AE isolate 92TH021.
Two of the antibodies with the most complete neutralization
against the indicator panel of viruses, PGT151 and PGT152,
were then evaluated for neutralization against a much larger
panel of 117 cross-clade virus isolates in a TZM-bl pseudovirus
neutralization assay. PGT151 neutralized approximately 66% of
viruses with a median IC50 of 8 ng/ml, and PGT152 neutralized
64% of viruses with a median IC50 of 12 ng/ml (Table 1). These
bnAbs have IC50 values that are about 1 log lower than the V2
prototype bnAb PG9 (Table S2) and that are comparable to the
IC50 values that have been determined for the N332-glycan-tar-
geting bnAbs PGT121 and PGT128 on the same panel (Walker
Table 1. PGT151 and PGT152 Potency and Breadth of
Neutralization against a 117 Pseudovirus Panela
mAb PGT151 PGT152
Median IC50 or
IC80 (mg/ml)
IC50 IC80 IC50 IC80
0.008 0.024 0.012 0.034
Breadth (%) 66 44 64 47
aSee also Table S2.
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PGT151 Binds a gp41 Epitope on Cleaved HIV Trimeret al., 2011; Ferguson et al., 2013). However, it should be noted
that, for a significant fraction of virus isolates, as above, com-
plete neutralization was not achieved. PGT151 neutralized
26% of isolates to a level of <80%, and PGT152 neutralized
20% to the same level. We have previously described such
incomplete neutralization of HIV isolates by bnAbs PG9 and its
somatic variant PG16, and in part, we ascribed this phenomenon
to glycan heterogeneity (Doores and Burton, 2010). This also
appears to be the case for PGT151 and PGT152 (see below).
Of note, the percent of isolates that plateaued at <80% neutral-
ization was much higher for PGT151 and PGT152 than for PG9,
for which only about 1% of neutralized viruses showed this
behavior.
We have previously shown that JR-CSF gp120 released from
virus grown in PBMCs contains a higher percentage of complex
N-linked glycans (21%) than its pseudovirus counterpart (2%)
(Bonomelli et al., 2011). Therefore, we wanted to determine
whether the incomplete neutralization, achieved via pseudo-
virus, that was observed for the PGT151 family translated into
incomplete neutralization when the more relevant PBMC-grown
replication-competent virus was used. PGT151 family neutrali-
zation of JR-CSF, JR-FL, 93IN905, and 92RW020 pseudovirus
produced in 293T cells was compared to replication-competent
virus produced in PBMCs when TZM-bl target cells were used
(Figures S1A–S1D, first and second columns). In parallel to the
TZM-bl experiments, the replication-competent virus was also
assessed for neutralization in PBMCs (Figures S1A–S1D, third
column). Neutralization of 92RW009 replication-competent virus
was also assessed in TZM-bl and PBMC (Figure S1E). The lucif-
erase values for the TZM-bl neutralization assays were read after
a 3 day incubation, and the PBMC neutralization assays were
assessed for p24 levels on days 4 and 7. In general, somewhat
higher levels of saturation of neutralization were seen in assays
when replication-competent virus grown in PBMCs was used
andwhen PBMCswere employed as target cells. As an example,
PGT153, which did not neutralize 93IN905 pseudovirus entry into
TZM-bl cells, was able to neutralize 93IN905 replication-compe-
tent virus entry into these same cells, albeit modestly at 35%
maximum neutralization (Figures S1C and S1F). This plateau
increased to 70% when replication-competent viral entry into
PBMCs was evaluated. These results suggest that the breadth
and potency of PGT151 and PGT152 neutralization might be
somewhat underestimated in a pseudovirus-TZM-bl assay rela-
tive to an assay involving PBMC-grown replication-competent
virus and PBMCs as target cells.
We next compared neutralization by the PGT151 family
members with that of the donor serumon a smaller 25 virus panel
(Table S3). The composition of this panel, derived from the 117virus panel, was arrived at by selection of viruses showing a
range of sensitivities to PGT151. As shown in Table S3, all but
three of the viruses that were neutralized by the donor serum
were also neutralized by individual members of the PGT151
family. The IC50 values of PGT151 (r = 0.54, p value =
0.0263), PGT152 (r = .73, p value = 0.0013), PGT156 (r =
0.69, p value = 0.03), PGT157 (r = 0.73, p value = 0.03), and
PGT158 (r = 0.69, p value = 0.288) had an inverse correlation
to the donor-serum 50% neutralization titer (1/dilution). Incom-
plete neutralization by the donor serum also correlated with
incomplete neutralization by the PGT151 family members:
PGT152, PGT153, PGT155, PGT156, and PGT158. These results
indicate that the PGT151 family can largely recapitulate the
serum neutralization breadth and potency on this small virus
panel.
PGT151 and PGT152 bnAbs Bind Specifically to Cleaved
and Not to Uncleaved Env Trimers
ELISA studies showed that PGT151 and PGT152 do not bind
to monomeric gp120 from several viruses from multiple
clades, although they are able to potently neutralize the corre-
sponding viruses (Figure 2A and Figure S2A). PGT151 and
PGT152 also did not bind 293F-cell–produced gp41 trimers (Fig-
ure S2B), which are most likely in a 6 helix bundle conformation.
Surprisingly, PGT153 did show some binding to the gp41
trimeric protein, and of note, this antibody has the least
sequence identity to PGT151 and other family members (Table
S1). The results suggested that the antibodies might be largely
specific for native Env trimer. In order to investigate this possi-
bility, we measured the binding of PGT151 and PGT152 to
native cleaved and uncleaved variant JR-FL trimers on the
surface of 293T cells by flow cytometry. We chose this particular
isolate because it has previously been shown that fully cleaved
JR-FL Env is efficiently displayed on the surface of transfected
293T cells, whereas for most other isolates (Pancera and Wyatt,
2005), relatively high proportions of uncleaved trimers are
expressed. As shown in Figure 2B, PGT151 and PGT152
bind exclusively to cleaved variant JR-FL trimers and show no
binding to the corresponding uncleaved timers on the surface
of transfected cells. Cleavage was recently shown to be im-
portant for formation of native-like structure and presentation
of quaternary epitopes (Ringe et al., 2013). Together, these
data strongly argue that PGT151 and PGT152 are trimer specific
and, furthermore, are able to distinguish cleaved from uncleaved
trimers.
PGT151 and PGT152 were shown not to bind to a number of
recombinant, uncleaved gp140 preparations (Figure S2B),
which, although they contain three gp120 subunits attached to
trimeric gp41 ectodomains, adopt conformations that do not
resemble native Env trimers (Julien et al., 2013a; Lyumkis
et al., 2013; Ringe et al., 2013). However, PGT151 and PGT152
do bind well to the stabilized recombinant trimeric molecule
BG505 SOSIP.664 gp140 trimer (Figure 2C), which is a close
antigenic and structural mimic of the native Env trimer (Julien
et al., 2013a; Lyumkis et al., 2013; Ringe et al., 2013; Sanders
et al., 2013). PGT151 also distinguishes cleaved from uncleaved
BG505 SOSIP.664 gp140 trimers (Figure 2C).
No antibody demonstrating such an unambiguous cleaved
trimer reactivity profile has been described previously, althoughImmunity 40, 657–668, May 15, 2014 ª2014 Elsevier Inc. 659
Figure 2. PGT151 and PGT152 Binding to Different Forms of Env
(A) PGT151 and PGT152 do not bind to JR-FL gp120 monomer as mea-
sured by ELISA. Data for (A) and (C) are presented as the mean of two
replicates ± SEM.
(B) PGT151 binds to native, cleaved (cl) but not to uncleaved (uncl) JR-FL
E168K trimers expressed on the surface of 293T cells, as measured by flow
cytometry. Data are from a representative experiment of two replicate
experiments.
(C) PGT151 and PGT152 bind to cleaved soluble BG505 SOSIP.664 gp140
trimers but not to the corresponding uncleaved gp140 trimers, asmeasured by
ELISA.
See also Figure S2.
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PGT151 Binds a gp41 Epitope on Cleaved HIV Trimertrimer (Walker et al., 2009; Sanders et al., 2013) and cleavage (Li
et al., 2012) preferences have been reported.
PGT151 and PGT152 Bind to Complex Tri- and Tetra-
Antennary Glycans
Given that the less than 100% neutralization observed in a num-
ber of assays is reminiscent of the previously described glycan660 Immunity 40, 657–668, May 15, 2014 ª2014 Elsevier Inc.dependency of binding for some anti-HIV antibodies, we investi-
gated the ability of PGT151 and PGT152 to neutralize a number
of glycan-modified viruses. The glycosidase inhibitor swainso-
nine prevents the formation of complex glycans, and pseudo-
virus made in the mutant GNT1-deficient HEK293S cell line
(GNT1/) also does not contain complex glycans. As shown in
Figure 3A, PGT151 or PGT152 neutralization of JR-CSF virus
grown in the presence of swainsonine or in 293S cells was
greatly reduced in comparison to neutralization of wild-type
virus. Moreover, although PGT151 reacted well with BG505
SOSIP.664 gp140 trimers expressed in 293T cells, it did not react
with the same trimers derived from 293S cells (data not shown).
These results suggest that PGT151 andPGT152 bind to complex
glycans on Env.
To further investigate, we screened PGT151-158 for glycan
specificity by using several glycan microarrays. PGT151-158
bound tetra-antennary-complex-type N-glycans with terminal
galactose with and without terminal sialic acid residues (Fig-
ure 3B, Figure 3D, and Tables S4 and S5). Although terminal
sialic acid linked to the 6 position of galactose blocks binding
of the antibodies, sialic acid linked to the 3 position appears to
be accommodated. We note that in Figure 3B, the signal for tet-
rantennary N-glycan binding was saturated. In addition, most of
the PGT151 family antibodies also bound triantennary-complex-
type N-glycans with terminal galactose (Figures 3B and 3C),
although with lower avidity than the binding to tetra-antennary
glycans. Blattner et al. further confirmed these results by
showing that PGT151 and PGT152 bound to triantennary com-
plex glycans by using isothermal titration calorimetry (ITC) (Blatt-
ner et al., 2014, this issue). None of the antibodieswere observed
to interact with high-mannose glycans of the type demonstrated
to interact with the antibodies 2G12 and PGT128 or the bianten-
nary-complex glycan shown to interact with PGT121 (Figure 3C
and Tables S4 and S5).
Overall, we concluded that the binding of the PGT151 family is
glycan dependent but does not involve either of the high-
mannose-containing regions that have previously been found
to be important for broad neutralization. These regions are the
high-mannose gp120 patch around N332, recognized by anti-
bodies such as 2G12, PGT121, and PGT128, and the V2 loop
region around N160, recognized by antibodies such as PG9
and PG16 (Doores and Burton, 2010; McLellan et al., 2011;
Walker et al., 2011; Julien et al., 2013b; Kong et al., 2013b). Of
note, PG16 has recently been shown to interact on glycanmicro-
arrays with a terminally sialylated tetrantennary glycan. How-
ever, this glycan has a different sialic acid linkage than that of
the tetra-antennary glycan that interacts with PGT151–PGT158
(Shivatare et al., 2013). Taken together, these results indicate
that members of the PGT151 family of antibodies bind a
glycan-dependent Env epitope that has not been previously
characterized.
PGT151 Does Not Compete with Any Known bnAbs for
Binding to Env Spikes
We next epitope mapped PGT151, which is the somatic variant
showing the most complete neutralization, by analyzing known
bnAbs for competition for binding to cleaved Env spikes (Fig-
ure S3A). When PGT151 was prebound to JR-FL DCT Env tri-
mers expressed on the surface of 293T cells, it did not compete
Figure 3. PGT151–PGT158 Bind Complex-
Type Glycans
(A) PGT151 and PGT152 neutralization of JR-CSF
pseudovirus generated (1) in the presence of the
glycosidase inhibitor swainsonine, which prevents
the formation of complex glycans by inhibiting the
trimming of mannose residues from the Man-a6
arm of the GlcNAcMan5GlcNAc2 structure, or (2) in
293S cells (GNT1/ cells), a cell line that is defi-
cient in N-acetylglucosaminyltransferase I and is
unable to add a GlcNAc residue to the Man5
GlcNAc2 structure to permit processing to com-
plex glycans. Neutralization of JR-SCF pseudo-
virus by 2G12 is not affected by either (1) or (2)
because it binds exclusively to high-mannose
glycans on the glycan shield of Env. Data are
presented as the mean ± SEM.
(B) PGT151–PGT158 bind tetra-antennary com-
plex carbohydrates and that PGT151 addi-
tionally binds a triantennary glycan, on the
Wong glycan array. Data are presented as the
mean ± SD.
(C) Most of the PGT151 family MAbs do bind
triantennary complex-type glycans on the CFG
microarray.
(D) PGT151 and PGT152 bind a tetrantennary
complex-type glycan on the neoglycolipid micro-
array.
The symbols for common monosaccharides are
as follows: purple diamonds represent sialic
acid, yellow circles represent galactose, red
triangles represent fucose, blue squares repre-
sent N-acetyl glucosamine, and green circles
represent mannose. See also Tables S4 and S5.
Data for the CFG microarray are presented as
the mean ± SEM. Small differences in array
results might reflect differences in glycan coating
densities.
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PGT151 Binds a gp41 Epitope on Cleaved HIV Trimerwith bnAbs targeting the V2 loop N160-glycan-dependent
epitope recognized by bnAb PGT145 or the region around
N332 recognized by bnAbs PGT121, PGT128, PGT135, 2G12,
and PGT130. This result was consistent with the glycan
array data above. Additionally, when PGT151 was prebound to
JR-FL E168K trimers, PGV04 (Figure S3A) and CD4-IgG (Fig-
ure S3B) were still able to bind the trimers, suggesting that its
epitope did not significantly overlap with the CD4 binding site.
PGT151 did show partial competition with CD4 prebound to
cell-surface-expressed trimers (Figure S3C), which most likely
is due to conformational changes that occur on the trimer after
CD4 binding (Liu et al., 2008) and lead to partial disruption of
the PGT151 epitope.
It has previously been shown that MPER-targeting bnAbs 2F5,
4E10, and 10E8 do not bind well to cleaved JR-FL trimers on theImmunity 40, 657–surface of 293T cells (Chakrabarti et al.,
2011; Huang et al., 2012). In contrast,
2F5 and 4E10 have been shown to bind
well to uncleaved JR-FL trimers (Chakra-
barti et al., 2011). Because PGT151 binds
only to cleaved trimers, we were unable
to perform satisfactory competition ex-
periments with MPER-targeting bnAbsand PGT151. These results are further evidence that PGT151
binds to a previously unidentified epitope on Env.
PGT151 Binds to a Glycan-Dependent Epitope on gp41
Next, a large number of viruses containing alanine substitutions
in gp120 and gp41 were evaluated in the context of PGT151
neutralization of JR-CSF. As shown in Table S6A and Table 2,
only substitutions in gp41 had a significant effect on neutrali-
zation by PGT151. The substitutions that had the greatest effect
on IC50 and the level of maximum neutralization of JR-CSF were
N611D, N637K, E647A, and E647G. The former two substitu-
tions are expected to lead to the loss of the glycans at N611
and N637, occupied most likely by complex glycans (Go et al.,
2008, 2009). Next, we investigated the ability of PGT151 to
neutralize a panel of variants that had been generated in the668, May 15, 2014 ª2014 Elsevier Inc. 661
Table 2. The Effect of Single-Amino-Acid Substitutions on PGT151 Neutralization for Three HIV Isolatesa
aNeutralization activity is reported as the n-fold increase in IC50 value relative to wild-type andwas calculated with the equation (IC50mutant)/(IC50 wild-
type). Percent maximum neutralization is the plateau reached on the neutralization curve by the mAb. Boxes are color coded as follows: blue,
substitutions that had a negligible effect on IC50 or maximum neutralization; yellow, 4- to 9-fold increase in IC50; orange, 10- to 99-fold increase;
red, >100-fold increase in IC50; lavender, maximum neutralizationR 50%; brown, maximum neutralization < 50%; gray, virus not significantly infec-
tious; and ND, not done. Data are presented as the mean of two independent experiments. See also Table S6.
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PGT151 Binds a gp41 Epitope on Cleaved HIV TrimerLAI strain of HIV-1 (Table S6B). Again, the gp41 residues N611
and N637were found to be important. In addition, an A501T sub-
stitution in gp120 showed a significant if moderate effect (Table 2
and Table S6B). Finally, in the context of the isolate JR-FL, the
most marked effects occurred for substitutions leading to the
loss of glycans at N611 and N637. At 98.7% and 92.8% conser-
vation, residues N611 and N637, respectively, are extremely
highly conserved across the 30,324 viral sequences found in
the Los Alamos database. E647 is 90.2% conserved across
the viral sequences.
Given the evidence that some HIV glycan-dependent anti-
bodies can interact with differing sets of glycans in an isolate-
dependent context (McLellan et al., 2011) (D. Sok, personal
communication), we tested combinations of double substitu-
tions of N611A, N637A, and E647A in JR-CSF (clade B),
BG505 (clade A), JR-FL (clade B), 92RW020 (clade A),
94UG103 (clade A), and IAVI C22 (clade C) in comparison with
single substitutions in terms of their effects on PGT151 neutrali-
zation (Figure 4A). For all isolates, N611A consistently had the
greatest effect on IC50 and the maximum level of neutralization.
The single N637A and E647A substitutions had little to no effect
on the IC50 for most isolates and varying effects on themaximum
level of neutralization by PGT151. However, the N611A + N637A
and N611A + E647A double substitutions completely abrogated
neutralization of all isolates by PGT151. Use of PGV04 as a
control showed that the substitutions did not affect the IC50 or
maximum inhibition of this CD4bs bnAb (Figure 4B).
To determine whether the glycans at N611 and N637 were
the only combination of gp41 glycans that PGT151 uses for
binding, we made double substitutions of all four (N611, N616,
N625, and N637) gp41 glycan combinations in JR-CSF (Fig-
ure S4A) and JR-FL (Figure S4C) and the four equivalent
(N611, N618, N625, and N637) gp41 glycan combinations in
BG505 (Figure S4B). No other combination of glycan substitution
other than N611A + N637A completely eliminated neutralization662 Immunity 40, 657–668, May 15, 2014 ª2014 Elsevier Inc.by PGT151. All other double-substitution combinations that
removed two glycans in gp41 (N625 and either N616 or N618)
in combination with either N611 or N637 had no additional
effects on neutralization beyond those elicited by the single
N611 or N637 substitution alone. The double substitution
N616A + N625A had no effect at all on neutralization by
PGT151. PGV04 was used as a control for these substitutions
for BG505 (Figure S4C), and PGV04 and 10E8 were used as
controls for the substitutions in JR-FL (Figure S4C). In addition,
double substitutions leading to the removal of the four gp41
glycans in JR-CSF were made in combination with N88A, which
would lead to the removal of a glycan that would not be expected
to be close to the PGT151 epitope (Julien et al., 2013a; Lyumkis
et al., 2013). These double substitutions had no effect on
PGT151 neutralization, in the sameway that the double substitu-
tions at N616 (or N618) and N625 had no effect on PGT151
neutralization.
gp120 glycan sites predicted, on the basis of structural
work (Julien et al., 2013a; Lyumkis et al., 2013; Blattner et al.,
2014), to be at or close to the PGT151 epitope were also
eliminated in combination with N611 or N637 for the JR-CSF
isolate (N230, N241, N276, and N448) (Figure S4A) and
the BG505 isolate (N234, N276, and N448) (Figure S4B). A
number of combinations did indeed have effects on the
maximum neutralization observed (Figures S4A and S4B).
Although the N234A + N637A substitution in BG505 lowered
the PGT151 percent maximum neutralization, this result
was isolate specific. However, the substitutions N448A +
N611A and N448A + N637A in JR-CSF and N448A + N611A
in BG505 increased the maximum neutralization of PGT151
over that found with the single N611A and N637A substitutions
alone. These results suggest that glycans in regions of gp120
in the PGT151 epitope or in close proximity to the PGT151
epitope can affect the ability of PGT151 to achieve 100%
maximum neutralization.
Figure 4. PGT151 Neutralization of Viruses Containing N611A, N637A, and E647A Single and Double Alanine Substitutions
Serial dilutions of antibody (A) PGT151 and (B) PGV04, used as a control, were preincubated with pseudovirus for 1 hr and then added to TZM-bl cells. Three days
after infection, luciferase values were measured and percent neutralization was calculated. See also Figure S4. Data are from a representative experiment of at
least two replicate experiments and are presented as the mean values of two replicate wells ± SEM.
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PGT151 Binds a gp41 Epitope on Cleaved HIV TrimerBlattner et al. fitted the high-resolution EM structure of BG505
SOSIP.664 into the reconstruction of the JR-FL:PGT151 Fab
complex and predicted that the PGT151 LC interacts with
N276 from one gp120 protomer and with N262 and N448 from
a second gp120 protomer (Blattner et al., 2014, this issue). The
removal of the glycan at N276 or N448 in BG505 or JR-CSF
backgrounds had no effect on PGT151 neutralization. Further-
more, the removal of the combination of glycans at N276 +
N611 or N276 + N611 had no further effects on PGT151 neutral-
ization as compared to the effects of virus lacking only the glycan
at N611 or N637, respectively. In contrast, the removal of theglycan at N448 in combination with N637 or N611 increased
PGT151 maximum neutralization compared to the neutralization
plateaus of virus lacking the single glycans at N611 or N637. This
suggests that the glycan at N448 affects PGT151 neutralization
only in the context of the loss of a glycan at N611 and/or N637
or of the presence of certain glycoforms at these positions.
Our data paint a complex picture of Env recognition by
PGT151. Many interactions appear to be isolate dependent,
and phenotypes might not manifest when single mutations are
introduced (e.g., N234 and N637 in BG505; Figure S4B). Thus,
PGT151 might use redundant or compensatory interactions.Immunity 40, 657–668, May 15, 2014 ª2014 Elsevier Inc. 663
Figure 5. ADCC by PGT151 and PGT152
(A) PGT151 and (B) PGT152 were titered for ADCC
activity against target cells infected with HIV-1
NL4-3, YU2, JR-CSF, and SIVmac239, and an
NK cell line (KHYG-1) expressing CD16 was used
as the effector cell. The killing of virus-infected
cells by ADCC is indicated by a loss of relative light
units (RLUs). SIVmac239 is used as a negative
control, and HIVIG is used as a positive control.
Data are presented as mean values of three
replicates ± SEM.
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PGT151 Binds a gp41 Epitope on Cleaved HIV TrimerFurthermore, at first glance our data might seem contradictory to
that of Blattner et al. in that the negative-stain EM data fitted into
the high-resolution EM structure indicate that the glycans at
N448 and N276 contact PGT151. However, we have previously
shown that removal of the N276 glycan, which forms contacts
with VRC01 as determined by crystal structure, actually
increases VRC01 neutralization potency in functional assays
(Falkowska et al., 2012). It appears that the VRC01 antibody
has evolved largely to avoid the obstruction of the N276 glycan
rather than to use it for a positive binding interaction. Thus,
functional and structural studies can be complementary in
providing understanding of the complex interaction of antibodies
with epitopes involving glycans.
PGT151 and PGT152 Mediate Antibody-Dependent,
Cell-Mediated Cytotoxicity and Are Not Polyreactive
Neutralizing antibodies of the appropriate isotype recognizing
native Env spikes might be expected to mediate killing of HIV-
infected cells by antibody-dependent, cell-mediated cytotoxicity
(ADCC). PGT151 and PGT152 were investigated in an ADCC
assay against target cells infected with NL4-3, YU2, or JR-CSF
viruses and were shown to mediate this effector activity (Fig-
ure 5). SIVmac239 was used as a negative control.
Finally, we found no evidence for polyreactivity of either
PGT151 or PGT152 when we screened against a panel of anti-
gens (Figure S5A), and PGT151 did not bind to HEp-2 cells in an
antinuclear antibody (ANA-HEp-2) indirect immunofluorescence
assay, indicating that it does not bind to nuclear or cytoplasmic
self-antigens (Figure S5B). These results indicate that PGT151
and PGT152 are not polyreactiive and that they have the capacity
tomediateADCC inaddition toneutralizing freevirus,whichcould
be significant for the in vivo anti-viral activity of the antibodies,
whether vaccine induced or administered passively.
DISCUSSION
The past few years have seen an explosion in the generation of
bnAbs to HIV (Burton et al., 2012; Kwong and Mascola, 2012;
Klein et al., 2013; Mascola and Haynes, 2013). Many of the
new bnAbs are directed to epitopes defined earlier but have
greater potency and/or breadth of neutralization against diverse
isolates (Walker et al., 2009, 2011; Wu et al., 2010; Scheid et al.,
2011; Huang et al., 2012). However, at least two gp120 epitope
regions involving protein and glycan recognition have been
described (Walker et al., 2009, 2011). One of these regions is a
V2 epitope dependent on a glycan at N160, whereas the other
is a cluster of epitopes involving conserved parts of the V loops
and centered on N332. Here, we describe a set of antibodies664 Immunity 40, 657–668, May 15, 2014 ª2014 Elsevier Inc.recognizing a previously undefined glycan-dependent epitope
on gp41. The two prototype antibodies from this set, PGT151
and PGT152, are very potent and neutralize about two-thirds
of a large panel of viral isolates with amedian IC50 approximately
10 ng/ml, although they show incomplete neutralization with
a significant fraction of viruses. The recognized epitope is
centered on the highly conserved glycan site at N611, and there
is involvement of another highly conserved glycan site at N637
and the less conserved residue E647. The relative contributions
of these individual residues appear to be isolate dependent.
Substitution of N611 consistently had an adverse effect on
neutralization by PGT151 and, in combination with other sub-
stitutions at N637 or E647, invariably led to complete abrogation
of antibody neutralization. Nevertheless, viruses resistant to
neutralization by PGT151 were identified in the large panel that
was tested; this panel contained both N611 and N637 glycan
sites. This is in line with previous studies on glycan-dependent
gp120 antibodies, for which crucial glycans have been identified
but for which changes in non-glycan-related amino acid residues
lead to resistance even in the presence of these crucial glycans
(Walker et al., 2009, 2011; McLellan et al., 2011; Doria-Rose
et al., 2012). Also of note, viruses lacking both the N611 and
N637 glycan sites tend to show lower infectivity than wild-type
viruses, suggesting that the absence of these sites might be
associated with a lower fitness in vivo and that this lower fitness
could be associated, at least in part, with their high levels of
conservation.
For JR-CSF, the N611D substitution completely abolished
PGT151 neutralization, whereas removal of the glycan at N611
by N611A or S613A substitution had somewhat lesser effects
on IC50 and percent maximum neutralization. Similarly, the
N637K substitution abolished PGT151 neutralization, whereas
N637A or T639A substitution only affected the percent maximum
neutralization. The stronger effect of N611D and N637K as
compared to that of N611A and N637A, were also seen in
PGT151 neutralization of these variants in the LAI background.
The effects of substitution thus appear to go beyond the loss
of glycans and suggest that PGT151 might bind to protein in
addition to glycan components on gp41. For JR-FL, N611D
andN611A substitutions produced comparable effects, whereas
the effects of N637K were more marked than those of N637A,
suggesting differences in the precise mode of recognition of
PGT151 for different Envs.
Blattner et al. determined the ability of PGT151 to bind to
variants of the BG505 SOSIP.664 trimer (Blattner et al., 2014,
this issue). The N611Q + N637Q double substitution also elimi-
nated binding of PGT151 in the context of the BG505 SOSIP.664
trimer. Some observed differences in the magnitudes of effects
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PGT151 Binds a gp41 Epitope on Cleaved HIV Trimerof single substitutions at N611 and N637 might reflect the
presence of the MPER of gp41 and the proximity of the viral
membrane in neutralization studies but not those using the
recombinant SOSIP protein. Similarly, some differences were
observed between neutralization studies and SOSIP binding
studies in terms of the effects of a number of gp120 substitutions
on PGT151 binding. Thus, a number of substitutions led to
decreased binding of PGT151 to BG505 SOSIP (Blattner et al.,
2014) but did not impact neutralization. The residues that
lowered binding but did not impact neutralization might have
had a general effect on the trimer structure of BG505 SOSIP.664
but not on trimer structure and/or accessibility of PGT151 to its
epitope in the context of virus neutralization. Alternatively, there
might be a strain-specific effect given that we made substitu-
tions in JR-CSF and LAI rather than BG505.
The glycans involved in interaction with PGT151 and PGT152
are probably complex in light of the fact that virus produced with
high-mannose glycans only is not neutralized; this idea is also
consistent with glycan array studies that show optimal binding
to tri- and tetra-antennary N-linked glycans. The ability of
PGT151 to recognize slightly different epitopes on different iso-
lates may at first seem surprising but has in fact been noted for
both V2- and N332-dependent HIV bnAbs (McLellan et al.,
2011) (D. Sok, personal communication). It appears that bnAbs
recognizing neighboring glycans can employ varying modes of
recognition to the extent that alternate glycans can be used on
different isolates in some cases. Detailed molecular understand-
ing of how promiscuous binding is achieved for the PGT151
family of antibodies must await high-resolution structures of
these antibodies in complex with Env.
Similar to the V2-glycan-dependent bnAbs such as PG9 and
PG16, the PGT151 family of antibodies shows incomplete
neutralization behavior in the TZM-bl and PBMC assays, i.e.,
members of this family show neutralization curves that plateau
at less than 100% for a fraction of viral isolates. For PG9, incom-
plete neutralization has been ascribed, at least in part, to glycan
heterogeneity (Doores and Burton, 2010). This seems to also be
the case for the PGT151 antibodies: we have shown that gp120
glycans that are in close proximity to the PGT151 epitope can
affect neutralization by PGT151. Of note, the extent of incom-
plete neutralization appears to be generally less in an assay
involving replication-competent, PBMC-grown viruses infecting
PBMCs than in assays that use the corresponding pseudo-
viruses grown in 293T cells or replication-competent, PBMC-
grown viruses infecting TZM-bl cells. The impact of incomplete
neutralization on the protective ability of antibodies in vivo has
not yet been clearly established.
One of the most striking features of PGT151 and PGT152 is
that they are specific for cleaved Env trimer and do not recognize
uncleaved Env trimer. This behavior is seen in the context of
trimer expressed on the surface of infected cells and in the
context of a recombinant trimer that mimics virion-expressed
trimer. The gp41 components of the uncleaved soluble gp140
proteins have previously been shown to adopt a 6 helix bundle
conformation, whereas the gp41 components in the context of
the cleaved SOSIP trimers retain the prefusion form (Guttman
et al., 2013; Julien et al., 2013a; Lyumkis et al., 2013; Ringe
et al., 2013). Hence, PGT151 and PGT152 report on the con-
formation of gp41 and trimeric Env and should be valuable indistinguishing different forms of Env as found in a number of
potential immunogens, e.g., VLPs. The antibodies also appear
to stabilize the cleaved Env trimer (Blattner et al., 2014, this
issue), and this property might be crucial in structural studies
on functional spikes isolated from infected cell surfaces.
Finally, the PGT151 family of antibodies defines what is, to the
best of our knowledge, a previously unidentified, broadly neutral-
izing target on the HIV envelope spike; after molecular character-
ization, this target could be incorporated into vaccine designs.
The prevalence of the PGT151 specificity in donors with broadly
neutralizing sera is most likely limited in light of earlier obser-
vations on the predominance of neutralizing specificities (Walker
et al., 2010). However, more precise understanding of preva-
lence will require the use of the distinguishing features presented
in this study to characterize sera from a number of cohorts of
infected individuals.
EXPERIMENTAL PROCEDURES
Isolation of Monoclonal Antibodies
Themethod for isolating humanmonoclonal antibodies frommemory B cells in
circulation has previously been described (Walker et al., 2009).
Pseudovirus Generation
The generation of pseudoviruses incorporating Envs from different HIV-1
strains and/or containing single alanine substitutions is fully described else-
where (Pantophlet et al., 2003). Swainsonine was added at the time of trans-
fection for the glycosidase inhibitor experiments and was used at 20 mM.
Neutralization Assay
The neutralization activity of antibodies against pseudovirus was measured
with a TZM-bl assay as previously described (Li et al., 2005). Neutralization
of PBMC-grown, replication-competent virus was evaluated with the TZM-bl
assay as described above or with human PBMCs. For neutralization via
PBMCs, antibody and virus were preincubated for 1 hr at 37C before being
added to the stimulated PBMCs in a 96-well plate. The cells were incubated
for 24 hr, washed three times, and incubated for 4–7 days. p24 was read on
day 4 and day 7 after infection.
ELISA
Ninety-six-well plates were coated overnight at 4C with anti-gp120 antibody
D7324 (International Enzymes) at 5 mg/ml in PBS. Plates were washed four
times with PBS (0.05% Tween), either gp120 protein or lysed virus (931N905
or 94UG103) was added, and preparations were incubated for 2 hr at 37C.
The remainder of the experiment was conducted as previously described
(Falkowska et al., 2012). The gp140 and gp41 proteins were directly coated
onto the ELISA plates. The polyreactivity ELISA was performed as previously
described (Walker et al., 2009).
ELISA with BG505 SOSIP.664 Trimer
The procedure for the Ni-NTA ELISA has been previously described (Bontjer
et al., 2010). In brief, 0.1 mg/ml of His-tagged BG505 SOSIP gp140 was added
in PBS to Ni-NTA His Sorb 96-well plates (QIAGEN) for 1 hr at 37C.Wells were
washed four times with PBS (0.05% Tween 20). MAbs were added at a serial
dilution in 1%BSA in PBS for 2 hr at 37C.Wells were washed and anti-human
IgG F(ab0)2-HRPwas added at 1:5,000 dilution for 45min at room temperature.
Wells were washed, and a 1:1 TMB substrate solution (Pierce) was added for
colorimetric detection. The colorimetric reaction was stopped with 2N H2SO4,
and absorption was measured at 450 nm. Uncleaved tagged BG505 SOSIP
was generated by replacement of the optimized cleavage site (RRRRRR) by
an uncleavable motif (SEKS) (Ringe et al., 2013). The ELISA for uncleaved
D7324-tagged BG505 SOSIP trimers and corresponding cleaved D7324-
tagged BG505 SOSIP was previously described (Ringe et al., 2013). In Fig-
ure 2C, mAb binding to uncleaved D7324-tagged BG505 SOSIP or cleaved
His-tagged BG505 SOSIP is shown. The data for cleaved D7324-taggedImmunity 40, 657–668, May 15, 2014 ª2014 Elsevier Inc. 665
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BG505 SOSIP.
Flow Cytometry
Serial dilutions (1:5) of PGT151, PGT152, PG9, b12, and b6 starting at 20 mg/ml
were added to JR-FL E168KDCT wild-type or uncleaved (REKR replaced
with SEKS)-transfected 293T cells and incubated for 1 hr at 37C on a plate
rocker. The plate was washed twice in FACS buffer (PBS, 10% FBS, 0.01%
sodium azide) and stained with a 1:200 dilution of R-phycoerythrin (PE)-conju-
gated AffiniPure F(ab0)2 fragment goat anti-human IgG1 F(ab0)2 (Jackson
ImmunoResearch). Binding was analyzed with flow cytometry as previously
described (Walker et al., 2009).
The Consortium for Functional Glycomics Glycan Microarray
Analysis
PGT151 and PGT152 were screened on a printed glycan microarray, version
5.0, from the Consortium for Functional Glycomics (CFG) as described previ-
ously (Blixt et al., 2004). Antibodies were used at 30 mg/ml and were precom-
plexed with 15 mg/ml secondary antibody (goat anti-human-Fc-rPE, Jackson
Immunoresearch) before addition to the slide. Complete glycan array data
sets for all antibodies can be found at http://www.functionalglycomics.org
through the public database of CFG under resource request number 2944.
Neoglycolipid Microarray Analysis
Analysis with neoglycolipid arrays (Feizi and Chai, 2004) was carried out as
described previously (Pejchal et al., 2011). In brief, PGT151 and PGT121
were analyzed at 50 mg/ml, and biotinylated anti-human IgG (Vector) was
then added at 5 mg/ml. The results for PGT128 and 2G12 were taken from
earlier experiments performed with different versions of the microarrays, as
described (Pejchal et al., 2011). The analyses were performed at 20C. The
full array data with 38 oligosaccharide probes are in Table S4.
Wong Glycan Microarray Analysis
Amine-functional glycans were printed in replicates of three onto NHS-acti-
vated glass slides at a 100 mM concentration as previously described (Liang
et al., 2011; Shivatare et al., 2013). Printed slides were incubated for 1 hr at
80%humidity, and o/n desiccation followed. Slideswere blockedwith ethanol-
amine (50 mM ethanolamine in borate buffer [pH 9.2]). Antibodies (10 mg) were
precomplexed with DyLight 649-AffiniPure mouse anti-human IgG-Fc (5 mg,
Jackson ImmunoResearch) for 1 hr at 4C. The sample was added to a glycan
array and incubated at 1 hr at 4C. The slides were washed sequentially in PBS
with 0.05% Tween-20, in PBS, and then in water. Arrays were scanned on a
ProScanArray HT (PerkinElmer) confocal slide scanner. Image analysis was
carried out with Genepix Pro 6.0 analysis software (Molecular Devices Corpo-
ration). Error bars represent the average percentage error for all data points re-
ported. The oligosaccharide probes and array data are shown in Table S5.
ADCC
ADCC activity was measured as previously described (Alpert et al., 2012).
CEM.NKR-CCR5-sLTR-Luc cells (1 3 10
6 cells), which contain a Tat-inducible
luciferase reporter gene, were infected with HIV-1NL4-3 (200 ng p24), HIV-1YU2
(1 mg p24), HIV-1JR-CSF (1 mg p24), or SIVmac239 (500 ng p27) by spinoculation
in the presence of polybrene (40 mg/ml) (EMD Millipore). Four days after in-
fection, CEM.NKR-CCR5-sLTR-Luc cells were washed three times and incu-
bated in 96-well plates with an NK cell line (KHYG-1) expressing CD16 at a
10:1 E:T ratio in the presence of serial dilutions of monoclonal antibodies or
purified immunoglobulin from HIV-1+ donors (HIVIG; NIH AIDS Reagent
Program, Division of AIDS, NIAID, NIH: Catalog #3957, HIV-IG from NABI
and NHLBI). After an 8 hr incubation, cells weremixedwith luciferase substrate
(BriteLite Plus; Perkin Elmer), and luciferase activity in relative light units (RLUs)
was measured with a Victor X4 plate reader (Perkin Elmer). ADCC activity was
calculated from the mean RLU for triplicate wells at each antibody concentra-
tion relative to the means for background and maximal RLUs from replicate
wells containing uninfected and infected cells, respectively, incubated with
NK cells but without antibody.
Statistics
Statistical analyses were done with Prism 6.0 for Mac (GraphPad).666 Immunity 40, 657–668, May 15, 2014 ª2014 Elsevier Inc.ACCESSION NUMBERS
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